Sino Biopharma’s M&A move pays off with big licensing deal
The Chinese drugmaker stands to gain more than $7 billion from a partnership with Germany’s Boehringer if its therapies can deliver clinical and commercial results Key Takeaways: Most of the…
Recent Articles
RELATED ARTICLES
-
Alphamab seals $2.2 billion licensing deal with AI biotech
9966.HK - Innovent’s $10.5 billion deal marks new model for China drugmakers
- The global leap: Chinese biopharma, athletic brands dip toes in global waters
-
Hengrui makes headway with novel drugs but investors bide their time
1276.HK600276.SHG
- Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
-
Drug setback leaves Ascletis with an all-in bet on weight loss
1672.HK
- Insilico revenue soars above $100 million on AI drug partnerships
